Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psychiatric-Diseases, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
School of Medicine, University College Cork, Cork, Ireland.
Schizophr Res. 2018 Oct;200:12-19. doi: 10.1016/j.schres.2017.08.022. Epub 2017 Sep 1.
Limitations in access to antipsychotic-naïve patients and in the incisiveness of studies that can be conducted on them, together with the inevitability of subsequent antipsychotic treatment, indicate an enduring role for animal models that can inform on the pathobiology of neuromotor abnormalities in schizophrenia and related psychotic illness. This review focusses particularly on genetically modified mouse models that involve genes associated with risk for schizophrenia and with mechanisms implicated in the neuromotor abnormalities evident in psychotic patients, as well as developmental models that seek to mirror the trajectory, phenomenology and putative pathophysiology of psychotic illness. Such abnormalities are inconsistent and subtle in mice mutant for some schizophrenia risk genes but more evident for others. The phenotype of dopaminergic and glutamatergic mutants indicates the involvement of these mechanisms, informs on the roles of specific receptor subtypes, and implicates the interplay of cortical and subcortical processes. Developmental models suggest a criticality in the timing of early adversity for diversity in the relative emergence of psychological symptoms vis-à-vis neuromotor abnormalities in the overall psychosis phenotype. These findings elaborate current concepts of dysfunction in a neuronal network linking the cerebral cortex, basal ganglia, thalamus and cerebellum. Both findings in model systems and clinical evidence converge in indicating that any distinction between 'psychomotor' and 'neuromotor' abnormality is artificial and arbitrary due to a unitary origin in developmentally determined systems/network dysfunction that underlies the lifetime trajectory of psychotic illness.
抗精神病药物初治患者的可及性有限,且对其进行的研究也缺乏深入性,再加上后续不可避免地需要进行抗精神病药物治疗,这表明动物模型在精神分裂症和相关精神病性障碍的神经运动异常的病理生物学研究中仍具有持久的作用。本综述特别关注涉及与精神分裂症风险相关的基因以及与精神病患者中明显的神经运动异常相关的机制的基因修饰小鼠模型,以及试图反映精神病发病轨迹、表现和潜在病理生理学的发育模型。对于某些精神分裂症风险基因的突变小鼠,这些异常表现不一致且细微,但对于其他基因的突变小鼠则更为明显。多巴胺能和谷氨酸能突变体的表型表明这些机制的参与,说明了特定受体亚型的作用,并暗示了皮质和皮质下过程的相互作用。发育模型表明,早期逆境的时机对心理症状相对于整体精神病表型中的神经运动异常的相对出现具有关键性。这些发现阐述了目前关于连接大脑皮层、基底神经节、丘脑和小脑的神经网络功能障碍的概念。模型系统中的发现和临床证据都表明,“精神运动”和“神经运动”异常之间的任何区别都是人为的和任意的,因为这是由发育决定的系统/网络功能障碍的单一起源引起的,而后者是精神病终身发病轨迹的基础。